









Markets
/
Stocks
/
nasdaq-rptx
/

Repare Therapeutics Inc

RPTX

View Detailed Chart

1.500USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

64.34MMarket Cap

LossP/E TTM



Repare Therapeutics Inc

1.500

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

-0.66%

5 Days

-3.85%

1 Month

+4.17%

6 Months

+22.95%

Year to Date

+14.50%

1 Year

-54.41%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 3 analysts

BUY

Current Rating

5.000

Target Price

233.33%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Repare Therapeutics Inc

RPTX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(6)

Neutral(3)

Buy(2)

Indicators

Sell(2)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.014

Neutral

RSI(14)

50.243

Neutral

STOCH(KDJ)(9,3,3)

13.446

Oversold

ATR(14)

0.075

Low Volatility

CCI(14)

-79.699

Neutral

Williams %R

58.065

Sell

TRIX(12,20)

0.269

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.526

Sell

MA10

1.532

Sell

MA20

1.524

Sell

MA50

1.457

Buy

MA100

1.320

Buy

MA200

1.739

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.

Ticker SymbolRPTX

CompanyRepare Therapeutics Inc

CEOMr. Steve Forte

Websitehttps://www.reparerx.com/